Objective: To investigate the expression of Fermintin family homologous protein 2 (FERMT2) in non-small cell lung cancer and its clinical significance. Methods: Seventy-two patients with non-small cell lung cancer were collected at Xinxiang Central Hospital, Henan Province, from January 2015 to January 2017.There were 48 male and 24 female patients, the age ranged from 37 to 78 years (mean 58 years). The expression of FERMT2 in tumor samples and para-cancerous tissues were detected by immunohistochemistry. Protein and mRNA expression of FERMT2 were detected by Western blot and real-time fluorescence quantitative PCR, respectively. Western blot method was also used to detect integrin-related protein expression, including integrin beta 1 (CD29), vascular cell adhesion molecule (VCAM1), and mobile related protein-1 (MRP1). Results: Immunohistochemistry showed that the positive rates of FERMT2 expression were 81.9%(59/72)in carcinoma tissue and 15.4%(11/72) in para-cancerous tissues, and the difference was statistically significant (P<0.01). Positive FERMT2 expression was different in tumors at different tumor stages: 11/17 at stage Ⅰ, 16/20(80.0%)at stage Ⅱ, 17/20(85.0%)at stage Ⅲ, and 15/15 at stage Ⅳ, and there was a significant difference between each stage (P<0.01). By real-time PCR and Western blot, the expression of FERMT2 in non-small cell lung cancer tissues was significantly higher than that of para-cancerous tissue (P<0.01). The expression levels of integrin related proteins (integrin β1, VCAM1 and MRP1) in tumor tissues were significantly higher than those in para-cancerous tissues, and positively correlated with the expression of FERMT2 (r=0.531, P<0.01; r=0.483, P<0.01; r=0.612, P<0.01). Conclusions: FERMT2 is highly expressed in non-small cell lung carcinomas. Its expression is closely correlated with the tumor clinical stage. It is hypothesized that FERMT2 may promote tumor metastasis through interactions with integrin-like protein.
目的： 探讨Fermintin家族同源蛋白2(FERMT2)在非小细胞肺癌组织中的表达及其临床意义。 方法： 收集河南省新乡市中心医院2015年1月至2017年1月确诊并手术切除的非小细胞肺癌组织及相应的癌旁组织72例，其中男性48例，女性24例；患者年龄在37～78岁，中位年龄58岁。采用免疫组织化学ABC法检测非小细胞肺癌组织及其癌旁组织中FERMT2的表达水平，采用即时荧光定量PCR法和Western blot法检测非小细胞肺癌中FERMT2的mRNA及蛋白表达水平，同时采用Western blot法检测组织标本中整合素相关蛋白整合素β1(CD29)、血管细胞黏附分子(VCAM1)、移动相关蛋白1(MRP1)表达水平。 结果： 免疫组织化学法检测显示：FERMT2在非小细胞肺癌组织中表达阳性率为81.9%(59/72)，在癌旁组织中表达率为15.4%(11/72)，两者差异具有统计学意义(P<0.01)，在非小细胞肺癌分期中阳性表达比例为Ⅰ期11/17，Ⅱ期16/20(80.0%)，Ⅲ期17/20(85.0%)，Ⅳ期15/15，组间比较差异具有统计学意义(P<0.01)。荧光定量PCR和Western blot结果显示FERMT2在非小细胞肺癌组织中的表达显著高于癌旁组织(P<0.01)。肿瘤组织中整合素相关蛋白整合素β1、VCAM1以及MRP1表达水平显著高于癌旁组织，与FERMT2的表达呈正相关(分别为r＝0.531，P<0.01；r＝0.483，P<0.01；r＝0.612，P<0.01)。 结论： FERMT2在非小细胞肺癌组织中高表达，且与肿瘤分期密切相关，可能通过整合素类蛋白促进肿瘤的转移进展。.
Keywords: Carcinoma, non-small-cell lung; Integrins.